Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler

Size: px
Start display at page:

Download "Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler"

Transcription

1 Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler

2 At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations for preparing cumulative antibiograms. Discuss some problems in calculating %S statistics and how to address them. List points to consider when evaluating cumulative %S data.

3 CLSI M39-A3 Guideline Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data M39-A3 2009

4 CLSI M39-A3 Guideline describes preparation of a cumulative antibiogram report to be used to support clinical decisions re: empiric therapy of initial infections

5 Cumulative antibiogram Generally one big report, but increasing emphasis on segregating data to answer specific questions

6 What does it mean to be compliant with CLSI M39-A3? (1) Analyze/present data at least annually Include only final, verified results Include only species with 30 isolates Include diagnostic (not surveillance) isolates Include the 1 st isolate/patient, irrespective of body site overall antimicrobial susceptibility profile Include only drugs routinely tested Calculate %S (do not include %I)

7 What does it mean to be compliant with CLSI M39-A3? (2) Staphylococcus aureus list %S for all and MRSA subset Streptococcus pneumoniae list %S for cefotaxime / ceftriaxone / penicillin w/ meningitis and non-meningitis breakpoints list %S for penicillin w/ oral breakpoints, if appropriate Viridans streptococcus - list %S and list %I for penicillin

8 Special Circumstance (1) % Susceptible N Amx Cftrx Ctax Ery Lvx Pen (IV) Pen (oral) Sxt S. pneumoniae meningitis* nonmeningitis** %S calculated using: * meningitis breakpoints **non-meningitis breakpoints cont..

9 Special Circumstance.. S. pneumoniae %S (2) 1 Breakpoints differ for ceftriaxone, cefotaxime and penicillin based on diagnosis. 2 Susceptible breakpoint for S. pneumoniae in patients with meningitis is 0.5 µg/ml for ceftriaxone and cefotaxime and 0.06 µg/ml for penicillin. 3 Susceptible breakpoint for S. pneumoniae in patients with nonmeningitis infections is 1 µg/ml for ceftriaxone and cefotaxime and 2 µg/ml for penicillin. 4 Susceptible breakpoint for S. pneumoniae is 0.06 µg/ml for penicillin when penicillin is administered by the oral route.

10 Special Circumstance.. % Susceptible Option 1 N Clin Ery Ox Pen T-S T S Van All SA 1317* MRSA MSSA * All NOT sum of MRSA and MSSA because: analyzed 1 st /iso/patient from each subset, e.g., OX-R S. aureus 36 pts had both MRSA and MSSA CLSI M39-A3

11 Special Circumstance.. Option 2 % Susceptible N Clin Ery Ox* Pen T-S T S Van MRSA MSSA *68% of all S. aureus are oxacillin-s CLSI M39-A3

12 Exmp. combine 2 years of data when N is <30 isolates Morganella morgannii Year N %S Cipro # S %S Gent # S Total N %S = Total #S / Total N %S - 70 (28/40) - 88 (35/40) -

13 If you must report N <30, consider comment such as %S calculated from fewer than the standard recommendation of 30 isolates

14 Cumulative antibiogram data are impacted by Patient population served Culturing practices Antimicrobial susceptibility testing policies Temporal outbreaks Assumes individual susceptibility test results used for cumulative antibiogram are Final Verified Results!

15 Example: Healthcare facilities showing differences in %S for oxacillin and S. aureus %S oxacillin Facility type Geriatrics? Known MRSA outbreaks? Perform AST on all S. aureus? Facility #1 35% Tertiary care Yes Yes No Facility #2 50% Acute care No No Yes if comparing %S data, you must understand the basis of the data!

16 To interpret cumulative antibiogram, data you should know (1) Source of isolates Random? Special collection; any selection criteria? Patient demographics? Geographic region? Dates of collection? Fresh isolates? Frozen isolates? Could isolates be clonal?

17 To interpret cumulative data antibiogram, you should know (2) Laboratory testing Method used for organism identification and AST? Criteria used to define susceptible? All drugs tested on all isolates concurrently? Isolates tested by central lab or in individual labs? QC documented? Unusual results confirmed? Data analysis Eliminate duplicates? Does %S include %I? N (small N value has large 95% confidence interval)

18 What are the options for excluding duplicate patient isolates? Count one isolate of a given species / patient / year M39-A3 suggests 1 st isolate/patient Count duplicates after x days (e.g. 7, 30 days) elapsed since testing the previous isolate from a given patient Count duplicate isolates on a patient that have different results for one or more drugs (e.g., S to R, R to S) Count all isolates

19 How do various methods for excluding duplicates impact %S? P. aeruginosa - ciprofloxacin # isolates % Cipro-S 2.2 isolates/patient st iso/patient 30 days Phenotype All M39-A3 50 UCLA 2008

20 When might we examine more isolates than the 1 st isolate/patient? When data from additional isolates are needed to answer a specific question Examples: How many patients had MDR Acinetobacter baumannii? Were any S. aureus not susceptible to daptomycin?

21 What about MDR Acinetobacter baumannii? A. baumannii - meropenem 1.9 isolates/patient # isolates % Mero-S st iso/patient All 0 M39-A3 UCLA 2008

22 How many Acinetobacter baumannii were MDR? Category # Isolates # Patients Comments All # MDR???? 1 st st isolate/pt # MDR???? MDR only For 3/43 pts, MDR was not 1 st iso/pt MDR = R to: aminoglycosides; carbapenems; anti-pseudomonal cephalosporins, penicillins, fluoroquinolones UCLA 2008

23 What are some concerns for calculating %S? Not all drugs may be tested on each isolate of a given species When this occurs, comparing results for one drug against another may be misleading Selective testing of isolates from specific body sites

24 Concern: 1) separate panel for testing Enterobacteriaceae from urine; 2) testing large numbers of urine isolates can dilute data N Am Cz E. coli % Susceptible Cip Lvx Sxt Non-urine only Urine only NT 77 All Both cipro and levo tested on gram-neg (non-urine) panel; cipro tested only on urine panel CLSI M39-A3

25 Optional Report Strategy (include comment) N Am Cz % Susceptible Cip Lvx Sxt E. coli * 76 Levofloxacin tested on non-urine isolates only (N=292). Levofloxacin results should not be compared to results of other drugs, all of which were tested on all isolates (urine and non-urine, N=3636). CLSI M39-A3

26 Concern: reporting % VRE?? Protocols for AST of enterococci may vary among labs (UCLA tests sterile site isolates, urine isolates from inpatients, and on request) N Van % Susc Enterococcus spp. - bld Enterococcus spp. - all UCLA 2008

27 What about stratifying %S data to provide suggested empiric therapy recommendations for select patients / conditions? By specimen type or infection site By nursing unit or site of care By organism s s resistance characteristics By clinical service or patient population

28 Example of %S Data Stratification using cumulative antibiogram data to guide empiric therapy of acute uncomplicated urinary tract infections (UTIs)

29 Organisms Tested for AST UCLA 2008 (N = 15,645) E. coli NOT UR E. coli UR P. aeruginosa K. pneumoniae Other Other GP Other GN Enterococcus GN, gram-negative bacteria GP, gram-positive bacteria S. aureus

30 Managing Uncomplicated UTIs in Women Risk factors for resistance? Current or recent TMP-SMX or other antibiotic Recent hospitalization Recurrent UTI in past year No TMP-SMX resistance in community >20%? Yes Yes Use alternative agent: Fluoroquinolone (3 days) Or Nitrofurantoin (7 days) Fosfomycin (single dose) No TMP-SMX (3 days) Warren et al CID. 29:745. Warren et al CID. 29:745. Gupta, Hooton, and Stamm Ann Intern Med. 135:41.

31 Variability in Urine C&S Ordering Practices Clinical Scenario Probable uncomplicated UTI Previous treatment failure in older woman 1 No. (%) of general practitioners who said they would order C&S 165/278 (59%) 262/291 (90%) 1 more likely to have resistant organisms Hillier et al J Antimicrob Chemother. 58:1303. Hillier et al J Antimicrob Chemother. 58:1303. Patient with uncomplicated UTIs often not cultured!

32 E. coli Urine Isolates % S data from 2 facilities during similar time frame Data Source 10/11/04 1/31/05 CA university health care service 1 All pts. presenting with uuti symptoms Outpatients Cip UCLA Cumulative Antibiogram Report 2 2 %S from first isolate/pt (CLSI M39-A3) 3 Includes ER patients N 88 TMP-SMX Smith et al Clin Infect Dis. 46:689.

33 E. coli Urine Isolates %S 1 4 Patient Populations Category All patients Inpatients Outpatients yo female outpatients 2 N Am Cz Cip Fm T-S %S from first isolate/pt (CLSI M39-A3) 2 Includes ER patients UCLA 2008

34 E. coli Urine Isolates (N=998) yo Female Outpatients Resistance Profile N % No Resistance Am Am Sxt Am Cz Am Cip Sxt Am Cz Sxt Sxt Am Cip Am Cz Cip Sxt Drugs examined: Am, Cz, Cip,, Fm, Sxt Cip Other UCLA 2008

35 Example: empiric therapy policy change following clinical failure and review of cumulative antibiogram data Elderly male patient with cystitis seen in ER failed empiric ciprofloxacin Rx; previously empiric Rx successful Performed culture (previously no culture) which revealed cipro-r E. coli ER MD Question: what is cipro %S for urine isolates of E. coli from ER patients?

36 E. coli Urine Isolates %S ER vs. All Outpatients N Am Cz Cip Fm Sxt ER <65 yo ER 65 yo All Revised ER Policy; use cipro empirically only in patients <65 yo UCLA 2005

37 Stratifying %S Data for MDR Organisms If MDR (e.g., KPC) endemic, consider stratifying data (e.g., by unit or R mechanism) Minimize skewing of data Example: KPCs might be predominantly among ICU patients May not be seen in OB-GYN; single cumulative antibiogram would offer limited guidance for empiric therapy options for OB-GYN patients

38 Stratifying %S Data for MDR Organisms (e.g., ESBL, KPC) CLSI M39-A3

39 What about %S data for combinations of agents? Guide empiric therapy of infections where the likely causative organisms are best treated with combinations of antimicrobial agents Calculate %S to either (or both) of the two agents Does NOT imply synergy, antagonism or likely activity in vivo

40 P. aeruginosa % Susceptible* (N=726) Option 1 Cip Cftaz Mero Tob Cftaz +/or Cip Mero +/or Cip Cftaz +/or Tob Mero +/or Tob % S includes isolates that have any of these 3 profiles Cftaz S S R Tob S R S *analysis included 1 st isolate/patient UCLA 2008

41 P. aeruginosa (N=726 patients 1 ) Option 2 %S to 7 drugs and %S to either or both when 2 drugs are evaluated (%S for 2 drugs does NOT imply synergy, antagonism or likely activity in vivo) Ceftaz (74%) Mero (79%) Pip-taz 4 (69%) Cip (64%) Amik (94%) 2 98% Gent (80%) Tob (85%) Cip (64%) 1analysis included the most R result for each drug if patient had >1 isolate 2 %S for one drug - value in ( ) 3 %S for either or both drugs (e.g., %S to amik and/or ceftaz) UCLA used 16 µg/ml breakpoint for S

42 Patient JWR had 4 isolates of P. aeruginosa Isolate # Cip S R R R Gm R R R R Mero S S S S Most R result for each drug R R S

43 UCLA Resistance Trends (from UCLA Antimicrobial Susceptibility Summary) % Resistant MRSA PSA-Cip VRE E. coli-cip UCLA

44 Cumulative Antibiogram QA Check Ensure individual AST results on pt. isolates are verified before being sent to database Report species with 30 isolates Define abbreviations Include appropriate drugs for the species Only those with breakpoints in CLSI M100 for the species Check footnotes (e.g., only ampicillin, a fluoroquinolone, TMP-SMZ, 3 rd gen cephalosporin, chloramphenicol for Salmonella / Shigella)

45 Cumulative Antibiogram QA Check (con t) Get 100% S for drug/bug combinations with only S breakpoints in CLSI M100 (e.g., Streptococcus pneumoniae and vancomycin) Staphylococcus - %S OX should = %S for other β-lactams (except amp, amox,, pen which should have a lower %S) Ensure results for related drugs make sense Compare data to previous year; account for significant changes Compare local data to national data

46 Trouble-Shooting N % Susceptible Imip Vanco K. pneumoniae S. aureus

47 Trouble-Shooting N % Susceptible Imip Vanco K. pneumoniae a - S. aureus b a Were there outbreaks with R strain (e.g., KPC producer)? b Are the 2% (16 isolates) that were VISA or VRSA accounted for?

48 Tools for examining statistical significance of %S Table H1. 95% confidence intervals for selected sample sizes CLSI M39-A3

49 How reliable is a report of 80% S for E. coli and ciprofloxacin? 95% Confidence Intervals for %S with Selected Sample Sizes Sample size % S CLSI M39-A3

50 Tools for examining statistical significance of %S Table H2. For comparing changes in %S CLSI M39-A3

51 If 80% of E. coli are susceptible to ciprofloxacin, what decrease in %S would be statistically significant (P 0.05)? # Isolates % S 80% % % CLSI M39-A3

52 Where can we find %S data from around the globe? Publications CDC / state Public Health Dept websites Pharmaceutical company websites EARRS Other Some examples follow!

53

54 tance/antibio2007.pdf

55

56

57 ocuments/

58

59

60 Note: search for publications only

61

62 Summary (1) CLSI M39-A3 provides guidelines for preparation of a cumulative antibiogram to guide physicians in empiric therapy of initial infections. Cumulative antibiogram data are impacted by several factors to include: 1) culturing practices; 2) susceptibility testing policies; and 3) patient population served. The method used to exclude duplicate isolates on a given patient can impact cumulative antibiogram data. If drugs included in the cumulative antibiogram are only tested on select isolates,, data may be skewed.

63 Summary (2) It may be helpful to stratify %S data by one or more variables when developing empiric therapy guidelines for select patient populations, infections, etc. %S data for two drugs (e.g., %S to either of the two or both) may be helpful for guiding empiric therapy for suspected or confirmed infections caused by organisms generally treated with multiple agents. If the number of isolates is small,, the 95% confidence interval will be large. CLSI M39-A3 contains tools to help determine the statistical significance of changes in %S between time frames.

64 Summary (3) Each facility must customize cumulative antibiogram reports to optimize their use in that facility. There are several national and international sources of %S data. It is important to know source/nature of data used to construct the database when drawing conclusions. Although there are written guidelines for analysis and presentation of cumulative antimicrobial susceptibility test data, guidelines for use of these data are limited.

65

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM

UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER

More information

UNDERSTANDING THE ANTIBIOGRAM

UNDERSTANDING THE ANTIBIOGRAM UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe

More information

The Nuts and Bolts of Antibiograms in Long-Term Care Facilities

The Nuts and Bolts of Antibiograms in Long-Term Care Facilities The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado

More information

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

Leveraging the Lab and Microbiology Department to Optimize Stewardship

Leveraging the Lab and Microbiology Department to Optimize Stewardship Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

Analysis and Presentation of Cumulative Antibiograms: ANewConsensusGuidelinefromtheClinicaland Laboratory Standards Institute

Analysis and Presentation of Cumulative Antibiograms: ANewConsensusGuidelinefromtheClinicaland Laboratory Standards Institute INVITED ARTICLE MEDICAL MICROBIOLOGY L. Barth Reller and Melvin P. Weinstein, Section Editors Analysis and Presentation of Cumulative Antibiograms: ANewConsensusGuidelinefromtheClinicaland Laboratory Standards

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

Detecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)

Detecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP) Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

EARS Net Report, Quarter

EARS Net Report, Quarter EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,

More information

Dr Neeraj Goel Sr. Consultant Department of Clinical Microbiology. Sir Ganga Ram Hospital

Dr Neeraj Goel Sr. Consultant Department of Clinical Microbiology. Sir Ganga Ram Hospital Dr Neeraj Goel Sr. Consultant Department of Clinical Microbiology Sir Ganga Ram Hospital Resistance profile of MDROs in ICU: Quinolone: 80% Amikacin: 75% Cefaperazone sulbactum: 79% Carbapenems: 79% Super

More information

HUSRES Annual Report 2007 Martti Vaara.

HUSRES Annual Report 2007 Martti Vaara. HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

What s next in the antibiotic pipeline?

What s next in the antibiotic pipeline? What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

Antimicrobial Resistance Trends in the Province of British Columbia

Antimicrobial Resistance Trends in the Province of British Columbia 655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program

More information

POLQM Quality Conference October 2 nd, 2017

POLQM Quality Conference October 2 nd, 2017 POLQM Quality Conference john.galbraith@viha.ca October 2 nd, 2017 Discuss the accuracy of results in microbiology, especially in susceptibility testing Review how well microbiology results are interpreted

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

National Surveillance of Antimicrobial Resistance

National Surveillance of Antimicrobial Resistance National Surveillance of Antimicrobial Resistance Report to Ministry of Health by Sri Lanka College of Microbiologists SLCM ARSP & NLBSA Technical Committees December 2014 National Surveillance of Antimicrobial

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

Taiwan Surveillance of Antimicrobial Resistance (TSAR)

Taiwan Surveillance of Antimicrobial Resistance (TSAR) Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,

More information

Main objectives of the EURL EQAS s

Main objectives of the EURL EQAS s EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)

More information

Rise of Resistance: From MRSA to CRE

Rise of Resistance: From MRSA to CRE Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance

More information

Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border

Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border Yvonne Vasquez, MPH W. Lee Hand, MD Department of Research

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi

More information

Guidelines for Treatment of Urinary Tract Infections

Guidelines for Treatment of Urinary Tract Infections Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2012 Authors: Maggie Heginbothom Robin Howe & Catherine Thomas Version: 1

More information

Rational management of community acquired infections

Rational management of community acquired infections Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?

More information

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml) Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an

More information

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of

More information

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control

More information

9.5 Antimicrobial Resistance

9.5 Antimicrobial Resistance 9.5 Antimicrobial Resistance Key Points In 215, there was a slight reduction in coverage of the Irish population by EARS-Net versus 214, from 1% to 97% There were 2,697 reports of invasive Escherichia

More information

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011 Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond

More information

ANTIMICROBIAL RESISTANCE IN KENYA; What Surveillance tells us

ANTIMICROBIAL RESISTANCE IN KENYA; What Surveillance tells us ANTIMICROBIAL RESISTANCE IN KENYA; What Surveillance tells us Sam Kariuki Kenya Medical Research Institute Introduction Although no systematic national surveillance is in place, few sentinel studies indicate

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective

Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective James E. Kirby, MD D(ABMM) Medical Director, Clinical Microbiology Beth

More information

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ... SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline

More information

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic

More information

Summary of the latest data on antibiotic resistance in the European Union

Summary of the latest data on antibiotic resistance in the European Union Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance

More information

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present

More information

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,

More information

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!

More information

Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?

Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical

More information

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,

More information

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST

More information

CUMULATIVE ANTIBIOGRAM

CUMULATIVE ANTIBIOGRAM BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

New Antibiotics & New Insights into Old Antibiotics

New Antibiotics & New Insights into Old Antibiotics New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University

More information

Hospital Acquired Infections in the Era of Antimicrobial Resistance

Hospital Acquired Infections in the Era of Antimicrobial Resistance Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information